Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is December - November.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 28, 2026	Nov 30, 2025	Nov 30, 2024	Nov 30, 2023	Nov 30, 2022	Nov 30, 2021
Net Income	-	-264.46	-193.57	-143.95	-180.36	-117.19
Depreciation & Amortization	16.44	18.86	16.43	13.65	10.81	6.08
Stock-Based Compensation	-	37.97	33.93	33.67	28.13	15.8
Other Adjustments	-8.58	-10.23	-11.26	-4.58	0.64	1.83
Change in Receivables	-9.5	-	-	-	6	-6
Changes in Accounts Payable	-0.91	-0.63	5.21	1.61	0.09	1.59
Changes in Accrued Expenses	3.45	17.31	11.82	3.12	7.49	6.22
Changes in Unearned Revenue	-14.83	-36.98	-28.55	19.51	-26.63	14.25
Changes in Other Operating Activities	-0.59	-11.3	-6.88	-4.13	-5.97	-6.94
Operating Cash Flow	-191.54	-249.47	-172.87	-81.08	-159.81	-84.37
Capital Expenditures	-6.84	-14	-9.27	-8.4	-12.24	-5.66
Purchases of Investments	-448.11	-455.69	-707.95	-246.33	-239.37	-348.5
Proceeds from Sale of Investments	430.11	617.54	459.51	323.04	278.81	245.91
Investing Cash Flow	98.99	147.85	-257.71	68.3	27.2	-108.25
Issuance of Common Stock	255.9	238.64	485.68	3.22	117.19	153.88
Repurchase of Common Stock	-	-	-0.02	-	-	-0
Net Common Stock Issued (Repurchased)	255.9	238.64	485.67	3.22	117.19	153.88
Financing Cash Flow	256.63	238.64	485.67	3.22	117.19	153.88
Net Cash Flow	-4.65	137.03	55.37	-9.85	-15.42	-38.73
Free Cash Flow	-198.37	-263.47	-182.14	-89.48	-172.05	-90.03
FCF Margin	-276.36%	-313.73%	-333.91%	-116.23%	-445.42%	-302.61%
Free Cash Flow Per Share	-2.13	-3.04	-2.71	-1.65	-3.54	-2.10
Levered Free Cash Flow	-298.55	-291.2	-204.82	-118.57	-206.82	-101.66
Unlevered Free Cash Flow	-319.38	-313.23	-224.57	-129.69	-210.33	-102.48

Updated Apr 8, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q